New pill may keep rare lymphoma in check after chemo
NCT ID NCT07414758
First seen Feb 21, 2026 · Last updated May 13, 2026 · Updated 15 times
Summary
This study tests whether a daily pill called golidocitinib can help keep peripheral T-cell lymphoma from coming back after successful first chemotherapy. About 136 adults who responded to initial treatment but cannot have a stem cell transplant will receive either the study drug or a placebo for up to 2 years. The main goal is to see how long the cancer stays under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai General hospital,Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200080, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.